title: Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography.
abstract: OBJECTIVE
  We investigated the effects of low-dose furosemide, administered with adequate hydration on contrast-induced nephropathy (CIN).
  
  
  METHODS
  A total of 859 patients scheduled to undergo coronary angiography or angioplasty were enrolled and randomly assigned to a furosemide treatment or control group. All patients received supplemental hydration. Immediately after surgery, patients in the furosemide group received intravenous furosemide injection (20 mg); those in the control group received no treatment. Total fluid intake and urine output were recorded. Pre- and postsurgical changes in serum creatinine levels (SCr), glomerular filtration rate (GFR) and creatinine clearance rate (CCr) were assessed, and the incidence of CIN was also evaluated between the two groups. Logistic regression analysis was used to study risk factors for CIN.
  
  
  RESULTS
  General baseline conditions were similar between the two groups. Patients who received furosemide had significantly less increase in SCr and a more marked increase in GFR and CCr than those who did not. The incidence of CIN was significantly higher in the control group. Logistic regression analysis revealed that female gender and angiotensin-converting enzyme inhibitor were risk factors for CIN, whereas furosemide acted as a protective agent.
  
  
  CONCLUSIONS
  With full hydration, small doses of furosemide can reduce CIN better than hydration alone.
authors: Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, China. guguoqiang72@yahoo.com.cn
authors: Guo-Qiang
authors: GQ
authors: Gu
authors: Rui
authors: R
authors: Lu
authors: Wei
authors: W
authors: Cui
authors: Fan
authors: F
authors: Liu
authors: Ying
authors: Y
authors: Zhang
authors: Xiao-Hong
authors: XH
authors: Yang
authors: Xue-Feng
authors: XF
authors: Chen
authors: Wan-Ming
authors: WM
authors: Jia
mesh_terms: D000328:Adult; D015906:Angioplasty, Balloon, Coronary; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003404:Creatinine / Q000378:metabolism; D004232:Diuretics / Q000008:administration & dosage*; D005260:Female; D005440:Fluid Therapy; D005665:Furosemide / Q000008:administration & dosage*; D005919:Glomerular Filtration Rate; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced / Q000517:prevention & control*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003287:Contrast Media; D004232:Diuretics; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005665:Furosemide; D003404:Creatinine